Cardiol Therapeutics Inc. (CRDL)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cardiol Therapeutics Inc. (CRDL) trades at $1.00 with AI Score 46/100 (Grade C). Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on developing therapies for cardiovascular disease. Market cap: $115.85M, Sector: Healthcare.
Price live · AI analysis from May 5, 2026Analyst Coverage for CRDL: CRDL does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CRDL against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CRDL: the 1 perspectives are evenly split.
How is this calculated? →Cardiol Therapeutics Inc. (CRDL) Healthcare & Pipeline Overview
Cardiol Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative anti-fibrotic and anti-inflammatory therapies for cardiovascular diseases. Its lead drug, CardiolRx, is currently undergoing Phase II/III clinical trials, positioning the company to address unmet needs in cardioprotection and myocarditis treatment within the specialty pharmaceuticals market.
What Is the Investment Thesis for CRDL?
Cardiol Therapeutics presents a focused investment opportunity within the cardiovascular therapeutics space. The company's lead product, CardiolRx, is in Phase II/III clinical trials, targeting significant unmet needs in COVID-19 related cardiovascular complications and acute myocarditis. Positive trial results could serve as a major catalyst, driving significant value appreciation. The development of a subcutaneous formulation of CardiolRx for heart failure also expands the potential market. However, as a clinical-stage company, Cardiol faces inherent risks related to clinical trial outcomes, regulatory approvals, and future funding requirements. With a market cap of $115.85M and a beta of 0.43, CRDL offers a potentially high-reward, high-risk investment profile, contingent on successful clinical development and commercialization.
Based on FMP financials and quantitative analysis
CRDL Key Highlights
- CardiolRx is currently in Phase II/III clinical trials, targeting COVID-19 related cardiovascular complications and acute myocarditis.
- The company is developing a subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart, addressing heart failure.
- Cardiol Therapeutics was incorporated in 2017, indicating a relatively young company focused on innovative therapies.
- The company is headquartered in Oakville, Canada, providing a base for its research and development activities.
- With 18 employees, Cardiol Therapeutics operates as a lean clinical-stage company focused on specific therapeutic areas.
Who Are CRDL's Competitors?
CRDL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $3.46 | +0.07% | $1.17B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
| ESALF Eisai Co., Ltd. | $25.00 | +0.00% | $7.05B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CRDL's Key Strengths?
- Lead product (CardiolRx) in Phase II/III trials.
- Focus on unmet needs in cardiovascular disease.
- Proprietary drug formulation.
- Experienced management team.
What Are CRDL's Weaknesses?
- Clinical-stage company with no currently approved products.
- Reliance on successful clinical trial outcomes.
- Limited financial resources.
- Small number of employees.
What Could Drive CRDL Stock Higher?
- Completion of Phase II/III clinical trials for CardiolRx in COVID-19 related cardiovascular complications.
- Completion of Phase II/III clinical trials for CardiolRx in acute myocarditis.
- Announcement of clinical trial results.
- Regulatory submissions for CardiolRx.
- Development of subcutaneous formulation of CardiolRx for heart failure.
What Are the Key Risks for CRDL?
- Financial-distress signal — its Altman Z-Score of 1.70 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure of Phase II/III clinical trials for CardiolRx.
- Regulatory delays or rejection of CardiolRx.
- Competition from other cardiovascular therapies.
- Difficulty in raising additional capital.
- Dependence on key personnel.
What Are the Growth Opportunities for CRDL?
- CardiolRx Clinical Trial Success: The successful completion of Phase II/III clinical trials for CardiolRx in treating COVID-19 related cardiovascular complications and acute myocarditis represents a significant growth opportunity. Positive results could lead to regulatory approval and commercialization, potentially capturing a substantial share of the market for these indications. The timeline for this opportunity is dependent on the trial's progress and regulatory review, with potential market entry within the next 2-3 years.
- Subcutaneous CardiolRx Formulation: The development of a subcutaneous formulation of CardiolRx for treating fibrosis and inflammation in the heart related to heart failure offers another key growth avenue. This formulation could provide a more convenient and effective treatment option for heart failure patients, expanding the market reach of CardiolRx. The timeline for this opportunity depends on preclinical and clinical development, with potential market entry in 3-5 years.
- Expansion into New Cardiovascular Indications: Cardiol Therapeutics could explore expanding the applications of CardiolRx into other cardiovascular indications beyond COVID-19 and myocarditis. This could include targeting other inflammatory heart conditions or exploring its potential in preventing cardiovascular events in high-risk patients. This expansion would require further research and clinical trials, with a potential timeline of 5+ years.
- Strategic Partnerships and Collaborations: Forming strategic partnerships with larger pharmaceutical companies or research institutions could accelerate the development and commercialization of CardiolRx and other pipeline products. These partnerships could provide access to funding, expertise, and distribution networks, enhancing Cardiol's growth prospects. The timeline for this opportunity is variable, depending on the availability of suitable partners and the terms of the agreements.
- Geographic Expansion: Expanding commercial operations beyond North America into Europe and other international markets represents a long-term growth opportunity for Cardiol Therapeutics. This would require establishing distribution networks and navigating regulatory approvals in different regions. The timeline for this expansion is dependent on the success of CardiolRx in initial markets and the availability of resources for international expansion, with a potential timeline of 5+ years.
What Opportunities Does CRDL Have?
- Positive clinical trial results for CardiolRx.
- Expansion into new cardiovascular indications.
- Strategic partnerships with larger pharmaceutical companies.
- Growing market for cardiovascular therapeutics.
What Threats Does CRDL Face?
- Failure of clinical trials.
- Regulatory hurdles.
- Competition from established pharmaceutical companies.
- Patent expiration.
What Are CRDL's Competitive Advantages?
- Proprietary drug formulation (CardiolRx).
- Patent protection for CardiolRx and its applications.
- Clinical trial data demonstrating efficacy and safety.
- Expertise in cardiovascular drug development.
What Does CRDL Do?
Cardiol Therapeutics Inc., incorporated in 2017 and headquartered in Oakville, Canada, is a clinical-stage life sciences company dedicated to the research and development of innovative therapies for cardiovascular diseases (CVD). The company's primary focus is on developing anti-fibrotic and anti-inflammatory treatments to address significant unmet needs in cardiology. Cardiol's lead product, CardiolRx, is a pharmaceutically produced cannabidiol formulation designed for use in cardiovascular medicine. Currently, CardiolRx is undergoing a Phase II/III multi-national, randomized, double-blind, and placebo-controlled clinical trial. This trial aims to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy in reducing cardiovascular and respiratory complications in patients hospitalized with COVID-19. Additionally, the trial is assessing the drug's potential in treating acute myocarditis, an inflammatory condition of the heart muscle. Beyond its current clinical trials, Cardiol Therapeutics is also actively developing a subcutaneous formulation of CardiolRx. This formulation is intended for the treatment of fibrosis and inflammation within the heart, which are critical factors in the development and progression of heart failure. By targeting these underlying mechanisms, Cardiol aims to provide novel therapeutic options for patients suffering from heart failure and other CVDs.
What Products and Services Does CRDL Offer?
- Researches and develops anti-fibrotic therapies.
- Researches and develops anti-inflammatory therapies.
- Focuses on treatments for cardiovascular disease (CVD).
- Develops CardiolRx, a pharmaceutically produced cannabidiol formulation.
- Conducts Phase II/III clinical trials for CardiolRx in COVID-19 related cardiovascular issues.
- Conducts Phase II/III clinical trials for CardiolRx in acute myocarditis.
- Develops a subcutaneous formulation of CardiolRx for heart failure treatment.
How Does CRDL Make Money?
- Develops and patents novel therapeutic formulations.
- Conducts clinical trials to demonstrate efficacy and safety.
- Seeks regulatory approvals for commercialization.
- Out-licenses or directly commercializes approved therapies.
What Industry Does CRDL Operate In?
Cardiol Therapeutics operates within the specialty and generic drug manufacturing industry, a segment of the broader healthcare sector. This industry is characterized by intense competition, stringent regulatory requirements, and a constant need for innovation. The cardiovascular disease therapeutics market is substantial, driven by an aging population and increasing prevalence of lifestyle-related conditions. Cardiol's focus on anti-fibrotic and anti-inflammatory therapies aligns with current trends in cardiovascular research, which emphasize targeted treatments for underlying disease mechanisms. The success of CardiolRx could position the company as a key player in this competitive landscape.
Who Are CRDL's Key Customers?
- Hospitals treating patients with COVID-19 related cardiovascular complications.
- Cardiologists treating patients with acute myocarditis.
- Patients suffering from heart failure.
- Potential pharmaceutical partners for licensing or co-development agreements.
FY2026 estForward Outlook
Wall Street analysts project Cardiol Therapeutics Inc. revenue of about $1.1M for fiscal 2026, with EPS near $-0.47. The estimate reflects 4 contributing analysts.
Key Financial Metrics
Its free cash flow yield is -14.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.39 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -22.4%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 2/9Financial Health
Cardiol Therapeutics Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 1.70 places it in the distress zone, a signal of elevated financial risk.
CRDL Valuation & Market Position
With a $115.85M market cap, Cardiol Therapeutics Inc. sits in the micro-cap segment of the market. Relative to its peer group, CRDL's quantitative score of 46/100 is below the peer average of 66/100.
CRDL Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Cardiol's pipeline, indicating a belief in upcoming breakthroughs.
- Community sentiment has shifted positively as recent trial updates hint at potential advancements in heart disease treatments.
- Increased media coverage has highlighted Cardiol's innovative approaches, attracting attention from both investors and healthcare professionals.
- Partnership discussions with larger pharmaceutical companies have sparked optimism about future collaborations and resource support.
Bear Case
- Concerns about regulatory hurdles have surfaced, as the approval process for new therapies can be lengthy and unpredictable.
- Market perception remains cautious due to the competitive landscape in the cardiovascular sector, with many players vying for attention.
- Some community members express skepticism regarding the scalability of Cardiol's technology, fearing it may not translate to widespread clinical use.
- Recent volatility in biotech stocks has led to a risk-averse sentiment, causing traders to be wary of investing in smaller firms like Cardiol.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · January 2026
CRDL Latest News
-
12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga · Jun 3, 2026
CRDL Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CRDL.
Price Targets
Wall Street price target analysis for CRDL.
CRDL MoonshotScore
What does this score mean?
The MoonshotScore rates CRDL's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: David G. Elsley
Unknown
Information about David G. Elsley's background is not available in the provided context. Therefore, a detailed career history, education, previous roles, and credentials cannot be provided. Further research would be needed to gather this information.
Track Record: Information about David G. Elsley's track record is not available in the provided context. Key achievements, strategic decisions, and company milestones under his leadership cannot be provided without additional information.
Cardiol Therapeutics Inc. Healthcare Stock: Key Questions Answered
What does Cardiol Therapeutics Inc. do?
Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease. Their lead product, CardiolRx, is a pharmaceutically produced cannabidiol formulation currently in Phase II/III clinical trials. These trials are evaluating its efficacy in reducing cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as its potential in treating acute myocarditis. The company is also developing a subcutaneous formulation of CardiolRx for treating fibrosis and inflammation in the heart associated with heart failure.
What do analysts say about CRDL stock?
Analyst coverage of Cardiol Therapeutics Inc. (CRDL) is not available within the provided context. Therefore, a summary of analyst consensus, key valuation metrics, and growth considerations cannot be provided. Further research on analyst ratings and reports would be needed to assess market sentiment and expectations for CRDL stock. This would typically include price targets, buy/hold/sell recommendations, and earnings estimates.
What are the main risks for CRDL?
As a clinical-stage pharmaceutical company, Cardiol Therapeutics faces significant risks inherent in drug development. The primary risk is the potential failure of its Phase II/III clinical trials for CardiolRx. Negative trial results would likely lead to a significant decline in the company's value. Other risks include regulatory hurdles in obtaining approval for CardiolRx, competition from established pharmaceutical companies with existing cardiovascular therapies, and the need to raise additional capital to fund ongoing research and development activities. Dependence on key personnel also poses a risk.
What are the key factors to evaluate for CRDL?
Cardiol Therapeutics Inc. (CRDL) holds an AI score of 46/100 (low). Not financial advice.
How frequently does CRDL data refresh on this page?
CRDL prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CRDL's recent stock price performance?
Cardiol Therapeutics Inc. (CRDL) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Lead product (CardiolRx) in Phase II/III trials. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CRDL overvalued or undervalued right now?
Valuing Cardiol Therapeutics Inc. (CRDL) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CRDL?
Before investing in Cardiol Therapeutics Inc. (CRDL), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on provided sources and may not be exhaustive.
- Financial data is limited to market cap and beta.
- CEO background and track record are unavailable.